HUTCHMED (China) (HMDCF) EPS (Weighted Average and Diluted) (2015 - 2021)
HUTCHMED (China) (HMDCF) reported EPS (Weighted Average and Diluted) of -$554428.6 for Q2 2021, down 166698529.72% quarter-over-quarter from $0.33 in Q4 2018.
HUTCHMED (China) (HMDCF) EPS (Weighted Average and Diluted) (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at -$554428.6 in Q2 2021.
- EPS (Weighted Average and Diluted) for Q2 2021 came in at -$554428.6, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was -$0.72 (up 47.37% YoY), and the FY2025 annual result was $0.52, up 1200.0% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$554428.6 in Q2 2021 per HMDCF's latest filing, from $0.33 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $143102.0 in Q2 2018 and troughed at -$554428.6 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -0.40 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.80 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -0.40 |
| 10 | HUTCHMED (China) | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -554,428.57 |
| Dec 31, 2018 | 0.33 |
| Jun 30, 2018 | 143,102.04 |
| Jun 30, 2016 | 8.51 Mn |
| Jun 30, 2015 | 1.33 |